Trial Profile
Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs AZD 5423 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.